281 related articles for article (PubMed ID: 37589044)
1. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
Lee MMP; Chan LL; Chan SL
J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
[TBL] [Abstract][Full Text] [Related]
2. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
3. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
5. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
7. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Kudo M
Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
[TBL] [Abstract][Full Text] [Related]
8. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
9. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract][Full Text] [Related]
10. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Cersosimo RJ
Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
[TBL] [Abstract][Full Text] [Related]
11. Paradigm shift in the treatment options of hepatocellular carcinoma.
Su TH; Hsu SJ; Kao JH
Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
[TBL] [Abstract][Full Text] [Related]
13. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
15. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
17. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
18. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
20. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Weinmann A; Galle PR
Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]